Tokyo Tape
Sign in
← Jmdc

Quarterly report · Q1

4483.TEDINET S100RPCP
Period2023-04-01 → 2023-06-30
Filed2023-08-14
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥6.7bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥27.8bn2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥5.8bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income¥2.5bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥1.1bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax¥2.6bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥5.9bn2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥1.1bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)¥2.0bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥4.3bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥765m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥2.0bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income¥759m2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥97.5bnat 2023-06-30Cons.Assets IFRS
Total assets¥98.6bnat 2023-03-31Cons.Assets IFRS
Total assets¥63.3bnat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥31.7bnat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥34.0bnat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥65.8bnat 2023-06-30Cons.Equity IFRS
Net assets / equity¥64.5bnat 2023-03-31Cons.Equity IFRS
Net assets / equity¥31.4bnat 2022-06-30Cons.Equity IFRS
Net assets / equity¥31.2bnat 2022-03-31dCons.Equity IFRS
Equity (owners)¥65.9bnat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥64.5bnat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥31.4bnat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥23.0bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥22.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥10.1bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥13.2bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥1.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥4.1bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥1.1bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥1.5bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥22.8bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥3.2bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥273m2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow¥28.3bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥909m2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥32.422023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥71.172022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥13.552022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥31.072023-04-01 → 2023-06-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥67.692022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥12.732022-04-01 → 2022-06-30Cons.Diluted earnings loss per share IFRS
Equity ratio67.5%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio65.5%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio49.7%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 36
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥76m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥76m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥151m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2023-04-01 → 2023-06-30¥969m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2023-04-01 → 2023-06-30¥919m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥50m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2023-04-01 → 2023-06-30¥87m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2023-04-01 → 2023-06-30¥4.5bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2023-04-01 → 2023-06-30¥4.5bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥25m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2023-04-01 → 2023-06-30¥1.3bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2023-04-01 → 2023-06-30¥448m
—segment totalrevenue2023-04-01 → 2023-06-30¥6.8bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥6.7bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥76m
—segment totalsegment profit2023-04-01 → 2023-06-30¥1.8bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥58m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥90m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue2022-04-01 → 2022-06-30¥910m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue external2022-04-01 → 2022-06-30¥869m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥41m
jpcrp040300-q1r_E35308-000Dispensing Pharmacy Supportreportable segmentsegment profit2022-04-01 → 2022-06-30¥47m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue external2022-04-01 → 2022-06-30¥3.7bn
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥17m
jpcrp040300-q1r_E35308-000Healthcare Big Datareportable segmentsegment profit2022-04-01 → 2022-06-30¥1.1bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentrevenue external2022-04-01 → 2022-06-30¥1.2bn
jpcrp040300-q1r_E35308-000Tele Medicinereportable segmentsegment profit2022-04-01 → 2022-06-30¥439m
—segment totalrevenue2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥5.8bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥58m
—segment totalsegment profit2022-04-01 → 2022-06-30¥1.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 632
ItemContextValueUnit
Segment profit loss IFRSPrior1YTDDuration_ReconcilingItemsMember-90000000JPY
Segment profit loss IFRSPrior1YTDDuration1521000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember4472000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1307000000JPY
Revenue from external customers IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember919000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReportableSegmentsMember6698000000JPY
Revenue from external customers IFRSCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenue from external customers IFRSCurrentYTDDuration6698000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember25000000JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember－JPY
Intersegment revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember50000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReportableSegmentsMember76000000JPY
Intersegment revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-76000000JPY
Intersegment revenue IFRSCurrentYTDDuration－JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember4497000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember1307000000JPY
Revenue IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember969000000JPY
Revenue IFRSCurrentYTDDuration_ReportableSegmentsMember6774000000JPY
Revenue IFRSCurrentYTDDuration_ReconcilingItemsMember-76000000JPY
Revenue IFRSCurrentYTDDuration6698000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000HealthcareBigDataReportableSegmentMember1294000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000TeleMedicineReportableSegmentMember448000000JPY
Segment profit loss IFRSCurrentYTDDuration_jpcrp040300-q1r_E35308-000DispensingPharmacySupportReportableSegmentMember87000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReportableSegmentsMember1831000000JPY
Segment profit loss IFRSCurrentYTDDuration_ReconcilingItemsMember-151000000JPY
Segment profit loss IFRSCurrentYTDDuration1679000000JPY
Segment profit loss IFRSPrior1YTDDuration1521000000JPY
Segment profit loss IFRSCurrentYTDDuration1679000000JPY
Depreciation and amortization operating expenses IFRSPrior1YTDDuration444000000JPY
Depreciation and amortization operating expenses IFRSCurrentYTDDuration551000000JPY
Other income IFRSPrior1YTDDuration19000000JPY
Other income IFRSCurrentYTDDuration1458000000JPY
Other expenses IFRSPrior1YTDDuration14000000JPY
Other expenses IFRSCurrentYTDDuration40000000JPY
Operating profit loss IFRSPrior1YTDDuration1081000000JPY
Operating profit loss IFRSCurrentYTDDuration2546000000JPY
Finance income IFRSPrior1YTDDuration54000000JPY
Finance income IFRSCurrentYTDDuration20000000JPY
Finance costs IFRSPrior1YTDDuration16000000JPY
Finance costs IFRSCurrentYTDDuration14000000JPY
Profit loss before tax IFRSPrior1YTDDuration1120000000JPY
Profit loss before tax IFRSCurrentYTDDuration2552000000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)関東財務局長
Filing date cover pageFilingDateInstant2023-08-14
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第11期第１四半期（自　2023年４月１日　至　2023年６月30日）
Company name cover pageFilingDateInstant
Original text (Japanese)株式会社ＪＭＤＣ
Company name in english cover pageFilingDateInstantJMDC Inc.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　兼　ＣＥＯ　　野口　亮

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass